Key result
In patients with type 2 diabetes and STEMI treated with primary percutaneous coronary intervention, a mean daily insulin dose > 44 IU during hospitalization independently predicted major adverse cardiac events (OR 5.2).
Why the study?
Does a high in-hospital daily insulin dose predict major adverse cardiac events in patients with type 2 diabetes and STEMI treated with primary percutaneous coronary intervention?
Cohort (n=112)
No
Does a high in-hospital daily insulin dose predict major adverse cardiac events in patients with type 2 diabetes and STEMI treated with primary percutaneous coronary intervention?
Odds Ratio: 5.2 (95% CI 1.3–20.7)
p-value: p=0.02
In patients with type 2 diabetes and STEMI undergoing primary percutaneous coronary intervention, a high daily insulin requirement (>44 IU) during hospitalization is a strong independent predictor of 1-year major adverse cardiac events.
No takes yet. Share an insight, caveat, or question.
Should not yet change insulin management in diabetic STEMI; hypothesis-generating association needing prospective validation.
Jeżewski et al. (2014) conducted a cohort in Type 2 diabetes mellitus with ST-elevation myocardial infarction (n=112). Mean daily short acting exogenous insulin dose (DID) > 44 IU vs. Mean daily insulin dose ≤ 44 IU was evaluated on Major adverse cardiac events (MACE) consisting of death, recurrent nonfatal myocardial infarction, or the need for repeated coronary revascularization (OR 5.2, 95% CI 1.3-20.7, p=0.02). In patients with type 2 diabetes and STEMI treated with primary percutaneous coronary intervention, a mean daily insulin dose > 44 IU during hospitalization independently predicted major adverse cardiac events (OR 5.2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: